Upgrade to SI Premium - Free Trial

Novartis (NVS)

155.70 +1.77 (1.15%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/27/26)
- M&A (3/31/20 *Est)

Latest Headlines

Novartis wins EU approval for Cosentyx in rheumatic disease October 21, 2026 11:03 AM - StreetInsider Novartis ends mid-stage trial for Fabhalta in lupus nephritis October 16, 2026 1:37 PM - StreetInsider FDA approves Novartis drug Rhapsido for symptomatic dermographism October 7, 2026 12:48 PM - StreetInsider Novartis to present MS drug data at MSToronto2026 conference October 7, 2026 7:35 AM - StreetInsider Novartis (NOVN:SW) (NVS) PT Lowered to CHF130 at Morgan Stanley October 6, 2026 4:41 AM - StreetInsider EMA panel backs Novartis Cosentyx for rheumatic condition in EU September 18, 2026 11:00 AM - StreetInsider Novartis halts ALS drug development after mid-stage trial fails September 16, 2026 11:13 AM - StreetInsider Selloff in this biotech stock is overdone – Mizuho September 12, 2026 4:00 PM - StreetInsider Novartis (NOVN:SW) (NVS) PT Lowered to CHF105 at Berenberg September 11, 2026 2:46 AM - StreetInsider Big Pharma Setbacks Create a New Wave of Rebound Plays September 10, 2026 2:13 PM - StreetInsider Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market September 10, 2026 8:30 AM - StreetInsider Artisan Partners calls for Novartis board changes amid trial, acquisition failures September 10, 2026 6:42 AM - StreetInsider Artisan Partners calls for board shake-up at Novartis after drug trial setbacks - Reuters September 10, 2026 6:21 AM - StreetInsider HSBC Upgrades Novartis (NVS) to Hold September 10, 2026 3:59 AM - StreetInsider HSBC Upgrades Novartis (NOVN:SW) (NVS) to Hold September 10, 2026 3:19 AM - StreetInsider Novartis (NOVN:SW) (NVS) PT Lowered to CHF135 at Citi September 9, 2026 4:36 AM - StreetInsider RBC Capital Starts Novartis (NOVN:SW) (NVS) at Sector Perform September 9, 2026 3:38 AM - StreetInsider CLSA Reiterates Outperform (2) Rating on Novartis (NOVN:SW) (NVS) September 9, 2026 2:39 AM - StreetInsider Deutsche Bank Downgrades Novartis (NOVN:SW) (NVS) to Hold Following Today's 13% Selloff September 8, 2026 4:31 PM - StreetInsider Novartis DM1 drug trial misses primary endpoint in Phase III study September 8, 2026 6:09 AM - StreetInsider Form 6-K NOVARTIS AG For: Sep 08 September 8, 2026 6:05 AM - SEC Filing Novartis (NOVN:SW) (NVS) PT Raised to CHF130 at Barclays September 8, 2026 5:38 AM - StreetInsider Novartis (NVS) call put ratio 1.6 calls 1 put into share price lower before the bell September 8, 2026 5:27 AM - StreetInsider Form 6-K NOVARTIS AG For: Sep 04 September 4, 2026 5:22 PM - SEC Filing Novartis pelacarsen trial fails to meet primary endpoint September 4, 2026 4:52 PM - StreetInsider Novartis (NOVN:SW) (NVS) PT Raised to CHF150 at BofA Securities September 4, 2026 6:06 AM - StreetInsider Premarket movers: GoPro soars 80% as Sono Group soars on Sports One deal September 1, 2026 6:38 AM - StreetInsider Form 6-K NOVARTIS AG For: Sep 01 September 1, 2026 6:21 AM - SEC Filing Novartis MS drug remibrutinib meets Phase III trial goals September 1, 2026 6:04 AM - StreetInsider FDA approves Novartis Pluvicto for earlier-stage prostate cancer July 31, 2026 4:31 PM - StreetInsider Novartis (NOVN:SW) (NVS) PT Raised to CHF120 at Berenberg July 28, 2026 4:58 AM - StreetInsider Full Article List